CNR1 and depressive symptom measurement: The rimonabant trial and trials with other CB1 antagonists were terminated due to the increased depression, anxiety, and suicidality that was associated with these drugs, so it is unlikely that any data pertaining to how CB1 antagonists affect human sleep will be forthcoming in the near future.